Statin use and prostate cancer risk in a large population-based setting

Cancer Causes and Control

Volumn 19, Issue 7, 2008, Pages 767-774

  Boudreau, Denise M ^a   Yu, Onchee ^a   Buist, Diana S M ^a,b   Miglioretti, Diana L ^a,b  

^a CENTER FOR HEALTH STUDIES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer; HMG CoA reductase inhibitors; Lipid lowering drugs; Prostate cancer; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CERIVASTATIN; CYCLOOXYGENASE 2 INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEVALONIC ACID; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; PROSTATE SPECIFIC ANTIGEN; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; DRUG USE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION;

AGED; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 48149114863     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-008-9139-4     Document Type: Article

References (44)

1. National Cancer Institute SEER cancer statistics review. Bethesda. Available: http://seer.cancer.gov/csr/1975_2001. Accessed August 23, 2007
2. Sewester CS, Dombek CE, Olin BR, Kastrup EK, Hebel SK (2004) Drug facts and comparisons. Wolters Kluwer Health, St. Louis
3. RX List. The Top 200 Prescriptions for 2004 by U.S. Sales. Available at: http://www.rxlist.com/top200_sales_2004. Accessed May 10, 2005
4. Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508-519
5. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9:10-19
6. Goldstraw MA, Amoroso P, Kirby RS (2006) Do statins protect against prostate cancer? BJU Int 97:1147-1148
7. Olsen JH, Johansen C, Sorensen HT, McLaughlin JK, Mellemkjaer L, Steffensen FH et al (1999) Lipid-lowering medication and risk of cancer. J Clin Epidemiol 52:167-169
8. Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18:213-219
9. Murtola TJ, Tammela TL, Lahtela J, Auvinen A (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 16:2226-2232
10. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE (2007) Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 16:2213-2217
11. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC et al (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98:1819-1825
12. Blais L, Desgagne A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160:2363-2368
13. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S (2002) Statin use and the risk of breast and prostate cancer. Epidemiology 13:262-267
14. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A et al (2005) Statins and prostate cancer risk: a case-control study. Am J Epidemiol 162:318-325
15. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R et al (2007) Statin use and risk of prostate cancer in the California men's health study cohort. Cancer Epidemiol Biomarkers Prev 16:2218-2225
16. Singal R, Khurana V, Caldito G, Fort C (2005) Statins and prostate cancer risk: a large case-control study in veterans. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23:1004
17. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22:2388-2394
18. Kaye JA, Jick H (2004) Statin use and cancer risk in the general practice research database. Br J Cancer 90:635-637
19. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B et al (2005) Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 66:1150-1154
20. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Butler EG et al (2006) Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 26:298-303
21. Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120:833-843
22. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM (2007) Long-term follow-up of the west of Scotland Coronary Prevention Study. N Engl J Med 357:1477-1486
23. Bjerre LM, LeLorier J (2001) Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 110:716-723
24. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278
25. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006) Statins and cancer risk: a meta-analysis. JAMA 295:74-80
26. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23:8606-8612
27. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2006) Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 24:4808-4817
28. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM (2007) Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25:3462-3468
29. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR (2007) Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 16:416-421
30. Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom B (ed) Pharmacoepidemiology. John Wiley and Sons, Chichester, pp 223-239
31. Boudreau DM, Doescher MP, Jackson JE, Fishman PA (2004) Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38:1317-1318
32. Buist DS, LaCroix AZ, Brenneman SK, Abbott T (2004) A population-based osteoporosis screening program: who does not participate, and what are the consequences? J Am Geriatr Soc 52:1130-1137
33. Taplin SH, Ichikawa L, Buist DS, Seger D, White E (2004) Evaluating organized breast cancer screening implementation: the prevention of late-stage disease? Cancer Epidemiol Biomarkers Prev 13:225-234
34. Washington State Department of Health, Center for Health Statistics (2003) Washington State Vital Statistics, 2002. Available at: http://www.doh.wa.gov/ehsphl/chs/chs-data/Public/AnnSum_2002. Accessed 17 Sept 2004
35. Newton KM, Wagner EH, Ramsey SD, McCulloch D, Evans R, Sandhu N et al (1999) The use of automated data to identify complications and comorbidities of diabetes: a validation study. J Clin Epidemiol 52:199-207
36. Hosmer DW Jr, Lemeshow S (1999) Applied survival analysis: regression modeling of time to event data. John Wiley & Sons, New York
37. Hastie T, Tibshirani R, Friedman J (eds) (2001) The elements of statistical learning; data mining, inference, and prediction. Springer, New York
38. Agency for Healthcare Research and Quality (2006) The Guide to Clinical Preventive Services 2006. Available at: http://www.ahrq.gov/clinic/pocketgd.pdf. Accessed 25 July 2007
39. Duncan RE, El-Sohemy A, Archer MC (2005) Statins and cancer development. Cancer Epidemiol Biomarkers Prev 14:1897-1898
40. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL et al (2006) Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 98:700-707
41. Sprague JR, Wood ME (2006) Statins and breast cancer prevention: time for randomized controlled trials. J Clin Oncol 24:2129-2130; author reply 2130-2131
42. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D (2005) The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 173:1923-1925
43. Sivaprasad U, Abbas T, Dutta A (2006) Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 5:2310-2316
44. Platz EA (2007) Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer. Cancer Epidemiol Biomarkers Prev 16:2175-2180